Next Generation Biosimilars in Immuno-Oncology

Next Generation Biosimilars in Immuno-Oncology

Tuesday, March 30, 2021 2:20 PM to 2:40 PM · 20 min. (Africa/Abidjan)

Biosimilars

Keynotes: Biosimilars

Presentation

Information

Study design and study conduct from Early PK to Phase 3 Development of Immuno-oncology Biosimilars
Biomarkers, Companion Diagnostics and Patient-centric/Decentralized Clinical Trial Solutions
Regulatory Considerations for Immuno-oncology Biosimilar Clinical Development and Registration

Isagani (Gani) M. Chico, Executive Director and Head of the Americas Oncology Medical Group, Covance Clinical Development Services

Covance by Labcorp Covance by Labcorp is a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 26,000 people worldwide, we provide comprehensive drug development solutions and are on a mission to advance health and power clear, confident decisions. Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. Together with our clients, Covance by Labcorp supports the development of innovative, life-changing treatments. Visit us at www.covance.com.

Log in

See all the content and easy-to-use features by logging in